43O Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O

Fabian Trillsch, Aikou Okamoto, JW Kim, A. Reuss, M.J. Rubio Pérez, Mehmet Ali Vardar, V. Salutari, Jean‐Sébastien Frenel, Henna Kärkkäinen, N. Colombo, Anita Chudecka-Głaz, Peter Oppelt, S. Lheureux, C. Lamot, Tobias Engler, Robert M. Wenham, Shin Nishio, A. Correa, P. Harter, Carol Aghajanian